Earnings
Arcutis Lifts 2026 Sales Outlook To $535 Million–$545 Million As Zoryve Revenue Climbs 45%
Third-quarter profit edged up to $8.8 million even as selling and administrative costs jumped to $99.6 million.
ARQT
Arcutis Biotherapeutics (ARQT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Arcutis CFO Defers 2027 Guidance, Says Sales Will 'Inflect' As Simone Biles Campaign Lifts Spending 60%
The company raised its 2026 revenue range to $535 million to $545 million while selling costs climbed to $99.6 million.
SEC Filings
Arcutis Doubles Its Stock-Sale Program To $200 Million As Selling Costs Jump 60%
The ZORYVE maker says it expects no need for financing, yet its selling expenses are growing faster than its revenue.
SEC Filings
Arcutis Seats Former AbbVie Chief Medical Officer Rob Scott On Expanded Eleven-Member Board
The skin-disease drugmaker added a seat for Scott, 73, whose AbbVie tenure included more than 14 major approvals, the company said.